TriangleNCT00006353 · CITED IN SOURCE DOCUMENTS
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2012-09-24
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without temozolomide for glioblastoma multiforme. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed glioblastoma multiforme by biopsy or surgical resection Grade IV disease Initial diagnosis no greater than 6 weeks prior to study PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) AST or ALT less than 2.5 times ULN Alkaline phosphatase less than 2.5 times ULN No chronic hepatitis B or C Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No known HIV infection No medical condition that would interfere with oral medication intake (e.g., frequent vomiting or partial bowel obstruction) No other prior or concurrent malignancy except surgically cured carcinoma in situ of the cervix or nonmelanoma skin cancer No serious medical, psychological, familial, sociological, or geographical condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa No concurrent biologic therapy No concurrent immunotherapy Chemotherapy: No prior chemotherapy No other concurrent chemotherapy Endocrine therapy: At least 14 days of prior corticosteroids at a stable dose required Concurrent corticosteroids allowed Radiotherapy: No prior radiotherapy No concurrent stereotactic boost radiotherapy Surgery: See Disease Characteristics No concurrent surgery for tumor debulking Other: No other concurrent investigational drugs
- healthy Volunteers
- false
- maximum Age
- 70 Years
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- interventions
- name
- temozolomide
- type
- DRUG
- name
- radiation therapy
- type
- RADIATION
Study design
- primary Purpose
- TREATMENT
Enrollment
- count
- 575
- type
- ACTUAL
Registered outcome plans (not posted results)
Full study description
- brief Summary
- RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without temozolomide for glioblastoma multiforme. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.
- detailed Description
- OBJECTIVES: I. Compare the efficacy of radiotherapy with or without temozolomide in terms of overall survival in patients with newly diagnosed glioblastoma multiforme. II. Compare the toxicity profiles of these regimens in these patients. III. Compare the progression free survival of these patients treated with these regimens. IV. Compare the quality of life in these patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, age (under 50 vs 50 and over), WHO/ECOG performance status (0-1 vs 2), and extent of surgical resection (biopsy only vs complete or incomplete resection). Patients are randomized to one of two treatment arms. Arm I: Patients undergo radiotherapy 5 days a week for 6 weeks. Arm II: Patients undergo radiotherapy as in arm I concurrently with oral temozolomide daily for 6 weeks. Patients then receive adjuvant oral temozolomide alone on days 1-5 every 28 days for 6 courses beginning 4 weeks after completion of radiotherapy. Quality of life is assessed prior to the study, at week 4 during radiotherapy, at 4 weeks after completion of radiotherapy, at the end of courses 3 and 6 of adjuvant chemotherapy (arm II), and then every 3 months until disease progression. Patients are followed every 3 months until disease progression or death. PROJECTED ACCRUAL: A total of 520 patients (260 per treatment arm) will be accrued for this study within 3.5 years.
Source references
- references
- citation
- Linz U. Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466). Cancer. 2010 Apr 15;116(8):1844-6. doi: 10.1002/cncr.24950.
- pmid
- 20151424
- type
- BACKGROUND
- citation
- Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA; EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008 Mar 15;112(6):1337-44. doi: 10.1002/cncr.23297.
- pmid
- 18213621
- type
- BACKGROUND
- citation
- Mason WP, Cairncross JG. Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial. Nat Clin Pract Neurol. 2005 Dec;1(2):88-95. doi: 10.1038/ncpneuro0045.
- pmid
- 16932504
- type
- BACKGROUND
- citation
- Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011 Sep 20;77(12):1156-64. doi: 10.1212/WNL.0b013e31822f02e1. Epub 2011 Aug 31.
- pmid
- 21880994
- type
- RESULT
- citation
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.
- pmid
- 19269895
- type
- RESULT
- citation
- Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008 Jan;9(1):29-38. doi: 10.1016/S1470-2045(07)70384-4. Epub 2007 Dec 21.
- pmid
- 18082451
- type
- RESULT
- citation
- Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, van den Bent MJ, Weller M, Bottomley A. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007 Aug 6;97(3):302-7. doi: 10.1038/sj.bjc.6603876. Epub 2007 Jul 3.
- pmid
- 17609661
- type
- RESULT
- citation
- Mirimanoff R, Mason W, van den Bent M, et al.: Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus RT alone. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): Plenary-3, S2, 2007.
- type
- RESULT
- citation
- Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006 Jun 1;24(16):2563-9. doi: 10.1200/JCO.2005.04.5963.
- pmid
- 16735709
- type
- RESULT
- citation
- Bottomley A, Taphoorn M, Coens C, et al.: Predicting survival using health related quality of life scores in glioblastoma cancers: findings from an international phase III randomised controlled trial. [Abstract] J Clin Oncol 23 (Suppl 16): A-9601, 861s, 2005.
- type
- RESULT
- citation
- Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6767-71. doi: 10.1158/1078-0432.CCR-05-0722.
- pmid
- 16203762
- type
- RESULT
- citation
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331.
- pmid
- 15758010
- type
- RESULT
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-13fec8e54c73d4c17808
- requested nct id
- NCT00006353
- primary nct id
- NCT00006353
- source kind
- fda_spl_label
- source record id
- 40ceddc0-83a2-4b3b-8953-fd0078a41133
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- 1e9f28bd80b43447b1bb0d05139e8caa3de0cdc62534db5c0b224998c5632206
- payload
- application numbers
- NDA021029
- NDA022277
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-13fec8e54c73d4c17808
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00006353
- occurrences
- context exact
- 14 CLINICAL STUDIES 14.1 Newly Diagnosed Glioblastoma The efficacy of TEMODAR was evaluated in MK-7365-051 (NCT00006353), a randomized (1:1), multicenter, open-label trial. Eligible patients were required to have newly diagnosed glioblastoma. Patients were randomized to receive
- end
- 119
- exact text
- NCT00006353
- start
- 108
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/45/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 40ceddc0-83a2-4b3b-8953-fd0078a41133
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- f3c74a0fa07150f3a8dae398295cf40c91454ea021852dcc1c6ed9532ec88982
- spl effective time
- 20260220
- spl set id
- 046a9011-3911-4d3f-a15f-fbb56d5aad56
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-ea5ecaa4753d7acb7c37
- requested nct id
- NCT00006353
- primary nct id
- NCT00006353
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 00198fe0f12adc95541ac85332c2ad520be3a395e64c0725a029ea5082d743e5
- payload sha256
- 9ef549042dd0a31a85db4021ad17828b600b1c7aba2b51547afd07981b65a062
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-ea5ecaa4753d7acb7c37
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00006353
- occurrences
- context exact
- ; 95% CI, 0.78–0.91).[<a href="#cit/section_3.20">20</a>] </p> <p id="_743" tabindex="-1">A large multicenter trial (<a href="/clinicaltrials/NCT00006353">NCT00006353</a>) of patients with glioblastoma, conducted by the EORTC-National Cancer Institute of Canada, reported a survival advantage with the use of tem
- end
- 80826
- exact text
- NCT00006353
- start
- 80815
- context exact
- 78–0.91).[<a href="#cit/section_3.20">20</a>] </p> <p id="_743" tabindex="-1">A large multicenter trial (<a href="/clinicaltrials/NCT00006353">NCT00006353</a>) of patients with glioblastoma, conducted by the EORTC-National Cancer Institute of Canada, reported a survival advantage with the use of temozolomide in
- end
- 80839
- exact text
- NCT00006353
- start
- 80828
- context exact
- py):</p> <div class="pdq-content-list"><ol id="_1271"><li>Standard therapy is based on a large, multicenter, randomized trial (<a href="/clinicaltrials/NCT00006353">NCT00006353</a>) conducted by the EORTC and National Cancer Institute of Canada (NCIC). This trial reported a survival benefit with concurrent radiation thera
- end
- 123678
- exact text
- NCT00006353
- start
- 123667
- context exact
- <div class="pdq-content-list"><ol id="_1271"><li>Standard therapy is based on a large, multicenter, randomized trial (<a href="/clinicaltrials/NCT00006353">NCT00006353</a>) conducted by the EORTC and National Cancer Institute of Canada (NCIC). This trial reported a survival benefit with concurrent radiation therapy and temozo
- end
- 123691
- exact text
- NCT00006353
- start
- 123680
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/865e7a313be74281ba.html
- source file sha256
- 00198fe0f12adc95541ac85332c2ad520be3a395e64c0725a029ea5082d743e5
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:31.446649+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 313573c355641616d4b5e97efef760e3f0ef1d7281e3b5c825af29ea09137135
- source title
- Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: March 28, 2025
- datetime
- 2025-03-28T12:00:00Z
- display
- March 28, 2025
Preserved source evidence · Not medical advice